4D Molecular Therapeutics FDMT Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's accrued progress collections and price adjustments?
- 4D Molecular Therapeutics (FDMT) reported accrued progress collections and price adjustments of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's accrued progress collections and price adjustments changed year-over-year?
- 4D Molecular Therapeutics's accrued progress collections and price adjustments increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's accrued progress collections and price adjustments?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's accrued progress collections and price adjustments has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.